Iraqi regulatory authority current system and experience with biosimilars

• Published in: Regulatory toxicology and pharmacology Vol. 117; p. 104768
• Main Authors: Al-Kinani, Khalid K., Ibrahim, Mazin J., Al-Zubaidi, Ruaa F., Younus, Manal M., Ramadhan, Samir H., Kadhim, Hussein J., Challand, Rodeina
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2020
• Subjects: biosimilars; Cost savings; Experience; Guidelines; Interchangeability; Iraq; Pharmacovigilance; Regulatory authority; Experience; Cost savings; biosimilars; Iraq; Pharmacovigilance; Interchangeability; Regulatory authority; Guidelines
• ISSN: 0273-2300; 1096-0295
• DOI: 10.1016/j.yrtph.2020.104768

Biological medicines have significantly altered treatment for many patients with chronic diseases such as cancers, autoimmune diseases, and diabetes. However, the high cost of biological medicines has limited patients’ access to them. Iraq is one of the countries that have decided to increase access to these medicines through biosimilars, which are copies of originator biological medicines. Prior to 2019, the Iraqi National Regulatory Authority (NRA) had no clear guidelines in place for biosimilars uptake. Therefore, approvals of many biosimilars were delayed. As a response to that, a new pivotal committee was found within this authority, and the first version of Iraqi basis and guidelines for the approval of biosimilars was enacted. With the implementation of the Iraqi biosimilars guidelines and escalating the cooperation within the Iraqi NRA, many benefits have been attained in a short time including the approval of many essential biosimilar products which has resulted in a total cost savings estimated to exceed 50 million USD in just the year 2020. However, there are still some barriers towards making the utmost benefit from biosimilars in Iraq, such as lack of familiarity of these products among the Iraqi health care providers which requires appropriate biosimilars-awareness enhancement strategies. •Biosimilars can provide many advantages but can also challenge many NRAs.•Iraqi NRA experience with biosimilars can add to global experiences with biosimilars.•Having clear pathways can encourage biosimilars entry to countries.•Having regulations and guidelines can block inferior products from entering the market.•Faster uptake of biosimilars can save cost to healthcare systems and increase access to medicines.